The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma

5Citations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Pleural mesothelioma (PM) is a rare and aggressive disease that arises from the mesothelial cells lining the pleural cavity. Approximately 80% of PM patients have a history of asbestos exposure. The long latency period of 20–40 years from the time of asbestos exposure to diagnosis, suggests that multiple somatic genetic alterations are required for the tumorigenesis of PM. The genomic landscape of PM has been characterized by inter- and intratumor heterogeneity associated with the impairment of tumor suppressor genes such as CDKN2A, NF2, and BAP1. Current systemic therapies have shown only limited efficacy, and none is approved for patients with relapsed PM. Advances in understanding of the molecular landscape of PM has facilitated several biomarker-driven clinical trials but so far, no predictive biomarkers for targeted therapies are in clinical use. Recent advances in the PM genetics have provided optimism for successful molecular strategies in the future. Here, we summarize the molecular mechanism underlying PM pathogenesis and review potential therapeutic targets.

Cite

CITATION STYLE

APA

Paajanen, J., Bueno, R., & De Rienzo, A. (2022, November 1). The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma. International Journal of Molecular Sciences. MDPI. https://doi.org/10.3390/ijms232113422

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free